Anne Cleasby

Materials Science · Physical Sciences

27h-index3.7kcitations69works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Enzyme Structure and Function(15), Biochemical and Molecular Research(14), Fibroblast Growth Factor Research(11), Computational Drug Discovery Methods(8), Protein Structure and Dynamics(7)

Publications69 total

Supplementary Methods, Figures 1-4, Tables 1-2 from Potent, Selective Inhibitors of Fibroblast Growth Factor Receptor Define Fibroblast Growth Factor Dependence in Preclinical Cancer Models
2023Open Access
Data from Potent, Selective Inhibitors of Fibroblast Growth Factor Receptor Define Fibroblast Growth Factor Dependence in Preclinical Cancer Models
2023Open Access
Data from Potent, Selective Inhibitors of Fibroblast Growth Factor Receptor Define Fibroblast Growth Factor Dependence in Preclinical Cancer Models
2023Open Access
Supplementary Methods, Figures 1-4, Tables 1-2 from Potent, Selective Inhibitors of Fibroblast Growth Factor Receptor Define Fibroblast Growth Factor Dependence in Preclinical Cancer Models
2023Open Access
X-ray Screening of an Electrophilic Fragment Library and Application toward the Development of a Novel ERK 1/2 Covalent Inhibitor
Journal of Medicinal Chemistry·2022· 23 citedOpen Access
Crystallographic screening using ultra-low-molecular-weight ligands to guide drug design
Drug Discovery Today·2019· 95 citedOpen Access
The discovery of quinoline-3-carboxamides as hematopoietic prostaglandin D synthase (H-PGDS) inhibitors
Bioorganic & Medicinal Chemistry·2019· 22 citedOpen Access
ERK2 mini-fragment binding
2018· 46 cited
Identification of novel allosteric inhibitors through fragment-based drug discovery and X-ray crystallography  
Acta Crystallographica Section A Foundations and Advances·2015Open Access
Fragment-Based Discovery of Potent and Selective DDR1/2 Inhibitors
ACS Medicinal Chemistry Letters·2015· 60 citedOpen Access
356 Discovery of novel pyrido[2,3-b]pyrazine as fibroblast growth factor receptor (FGFR-1, 2, 3 & 4) kinase inhibitors with nanomolar affinity
European Journal of Cancer·2014· 1 cited
400 Optimization of novel pyrido[2,3-b]pyrazine based small molecule fibroblast growth factor receptor 1, 2, 3 & 4 (FGFR) inhibitors into a potential clinical candidate
European Journal of Cancer·2014
Abstract 4748: Discovery of JNJ-42756493, a potent fibroblast growth factor receptor (FGFR) inhibitor using a fragment based approach
Cancer Research·2014· 9 cited
Structure of the BTB Domain of Keap1 and Its Interaction with the Triterpenoid Antagonist CDDO
PLoS ONE·2014· 250 citedOpen Access
BTB domain of KEAP1
2014· 17 cited
BTB domain of KEAP1 C151W mutant
2014
Crystal Structure of Human Soluble Adenylate Cyclase Reveals a Distinct, Highly Flexible Allosteric Bicarbonate Binding Pocket
ChemMedChem·2014· 39 citedOpen Access
Identification of orally bioavailable small-molecule inhibitors of hematopoietic prostaglandin D2 synthase using X-ray fragment based drug discovery
MedChemComm·2013· 8 cited
Potent, Selective Inhibitors of Fibroblast Growth Factor Receptor Define Fibroblast Growth Factor Dependence in Preclinical Cancer Models
Molecular Cancer Therapeutics·2011· 32 citedOpen Access
Abstract 1361: Fragment based drug discovery of selective inhibitors of Fibroblast Growth Factor Receptor (FGFR)
Cancer Research·2011· 2 cited
page 1 of 4Next →

Frequent Co-authors

Christopher W. Murray(15), Harren Jhoti(13), Ian J. Tickle(10), Alan J. Wonacott(8), Valério Berdini(8), Gordon Saxty(6), Richard Charles Garratt(6), Martyn Frederickson(5), Jeff Yon(5), Marc O’Reilly(5), Michael J. Hartshorn(4), Philip J. Day(4), Amanda E. I. Proudfoot(4), Mark A. Payton(4), Timothy N. C. Wells(4), Sharna J. Rich(4), H.M. Pereira(4), Glória Regina Franco(4), Maarten R. Egmond(3), Caroline J. Richardson(3)